Combination antibody therapy has gained significant recognition in past two decades. It is now a preferred drug treatment for cancers such as lymphomas and solid tumors. Antibodies for modulating immune system has also achieved a significant success clinically. Combination antibody therapy are crucial strategies for treating patients suffering from hematological malignancies and solid tumors. This therapy for tumors is based on the fundamentals of cancer cell’s antigen expression. Combination antibody therapy can function through mediating changes in antigen or receptor functions or modulating the immune system or administering a drug that becomes temporarily united with the antibody, for targeting a specific antigen. According to the journal of oncology (JCO) it has been concluded that a combination of epratuzumab with rituximab was tolerable and had substantial effect in Non-Hodgkin’s Lymphoma (NHL). Nonetheless, auto immune disease such as rheumatoid arthritis can be treated by combination of alpha monoclonal antibody with low dose weekly of methotrexate. Additive effect of Rituxan anti-CD20 chimeric antibody with low dose chemotherapy can be effective in B-Cell Lymphoma.
View Sample Report @ http://www.persistencemarketresearch.com/samples/11740
The particular nature of the combination antibody therapy has led to more targeted and specific treatment of the cancer and tumor. Hence, become an attractive treatment in recent years due to its non-chemotherapy nature, which in turn gives a safe and secure process of killing the cancer and tumor cells. Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors. Owing to the ability of combination antibodies to specifically target tumor cells and cancer cells has been crucial for the advancement of monoclonal antibodies combination therapy so far due to that it is expected that the CAGR for combination antibody therapy market is tend to expand in near future. Combination antibody therapy market is anticipated to grow on the backdrop of increased effort for developing dual targeting of tumor antigens such as bi-specific ADC’s and novel strategies such as masked antibodies.
Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/11740
Requirement of safe and chemotherapy-free cancer treatments have led towards rise in demand for combination antibody therapy. Major part of the demand is expected to be under chronic lymphocytic leukemia. However, over the year significant number of antibodies and immune system modulators have been introduced in various other cancer treatments, which has shown positive effects of disease disposal. The more convenient way for drug administration has empowered the growth of these type of cancer treatments, which further offers more patient compliance. Furthermore, the rise in prevalence of cancer around the globe has been a positive sign for combination antibody therapy market that in turn is expected to underpin the growth in use of combination therapy.
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353